Peter Eu

4.3k total citations · 2 hit papers
55 papers, 3.1k citations indexed

About

Peter Eu is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Peter Eu has authored 55 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Radiology, Nuclear Medicine and Imaging, 26 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Peter Eu's work include Radiopharmaceutical Chemistry and Applications (24 papers), Prostate Cancer Treatment and Research (14 papers) and Medical Imaging Techniques and Applications (13 papers). Peter Eu is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (24 papers), Prostate Cancer Treatment and Research (14 papers) and Medical Imaging Techniques and Applications (13 papers). Peter Eu collaborates with scholars based in Australia, United States and Canada. Peter Eu's co-authors include Rodney J. Hicks, Michael S. Hofman, Grace Kong, Price Jackson, Amir Iravani, Tim Akhurst, Declan G. Murphy, Scott Williams, Shahneen Sandhu and John Violet and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Peter Eu

55 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

2018 815 citations Michael S. Hofman, John Violet et al. The Lancet Oncology profile →
Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

2018 339 citations John Violet, Price Jackson et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Eu Australia	26	1.8k	1.5k	989	618	415	55	3.1k
Michael Eisenhut Germany	27	2.4k 1.3×	2.2k 1.5×	1.0k 1.0×	597 1.0×	371 0.9×	90	4.2k
Peter Bernhardt Sweden	37	2.3k 1.2×	931 0.6×	1.2k 1.2×	1.3k 2.1×	688 1.7×	130	3.8k
Ghassan El‐Haddad United States	24	1.5k 0.8×	1.7k 1.1×	1.1k 1.1×	625 1.0×	373 0.9×	97	3.3k
Annika Loft Denmark	31	1.1k 0.6×	703 0.5×	1.2k 1.2×	1.0k 1.7×	674 1.6×	90	3.2k
Mahila Ferrari Italy	30	1.8k 0.9×	663 0.4×	1.2k 1.2×	1.2k 1.9×	703 1.7×	87	3.1k
Amir Iravani Australia	27	2.2k 1.2×	2.1k 1.4×	1.1k 1.1×	337 0.5×	145 0.3×	108	3.2k
Samer Ezziddin Germany	37	1.9k 1.0×	1.4k 0.9×	1.8k 1.8×	1.6k 2.5×	1.1k 2.6×	182	4.0k
Price Jackson Australia	22	1.7k 0.9×	1.6k 1.0×	625 0.6×	284 0.5×	114 0.3×	52	2.6k
Jan Tennvall Sweden	35	2.3k 1.3×	1.2k 0.8×	1.4k 1.4×	647 1.0×	292 0.7×	130	4.9k
Glenn Flux United Kingdom	35	2.9k 1.6×	1.2k 0.8×	556 0.6×	427 0.7×	322 0.8×	138	3.8k

Countries citing papers authored by Peter Eu

Since Specialization

Citations

This map shows the geographic impact of Peter Eu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Eu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Eu more than expected).

Fields of papers citing papers by Peter Eu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Eu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Eu. The network helps show where Peter Eu may publish in the future.

Co-authorship network of co-authors of Peter Eu

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Eu. A scholar is included among the top collaborators of Peter Eu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Eu. Peter Eu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Masset, Julien, Philippe Robin, Raphaël Tripier, et al.. (2021). Fully Automated 68Ga-Labeling and Purification of Macroaggregated Albumin Particles for Lung Perfusion PET Imaging. PubMed. 1. 778191–778191. 5 indexed citations

Crumbaker, Megan, Andrew O. Yam, Andrew Nguyen, et al.. (2020). Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN). European Urology Oncology. 4(6). 963–970. 31 indexed citations

Hofman, Michael S., et al.. (2018). A First-in-Human Study of ⁶⁸Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. Journal of Nuclear Medicine. 59(12). 1837–1842. 15 indexed citations

Hofman, Michael S., John Violet, Rodney J. Hicks, et al.. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. The Lancet Oncology. 19(6). 825–833. 815 indexed citations breakdown →

Violet, John, Price Jackson, Justin Ferdinandus, et al.. (2018). Dosimetry of ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. Journal of Nuclear Medicine. 60(4). 517–523. 339 indexed citations breakdown →

Emmett, Louise, Megan Crumbaker, Bao Ho, et al.. (2018). Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. Clinical Genitourinary Cancer. 17(1). 15–22. 126 indexed citations

Hofman, Michael S., Peter Eu, Price Jackson, et al.. (2017). Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of ⁶⁸Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. Journal of Nuclear Medicine. 59(4). 625–631. 51 indexed citations

Hofman, Michael S., Shahneen Sandhu, Peter Eu, et al.. (2017). Lutetium-177 PSMA (LuPSMA) theranostics phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA. Annals of Oncology. 28. v270–v270. 7 indexed citations

Roux, Pierre‐Yves Le, Tracy L. Leong, Stephen Barnett, et al.. (2016). Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. Cancer Imaging. 16(1). 24–24. 17 indexed citations

10.

Roux, Pierre‐Yves Le, Shankar Siva, Daniel Steinfort, et al.. (2015). Correlation of ⁶⁸Ga Ventilation–Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. Journal of Nuclear Medicine. 56(11). 1718–1723. 29 indexed citations

11.

Eu, Peter, et al.. (2014). The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma. Targeted Oncology. 10(1). 15–26. 16 indexed citations

12.

Kashyap, Raghava, Price Jackson, Michael S. Hofman, et al.. (2013). Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. European Journal of Nuclear Medicine and Molecular Imaging. 40(12). 1853–1860. 31 indexed citations

13.

Kasbollah, Azahari, et al.. (2013). Review on Production of 89Zr in a Medical Cyclotron for PET Radiopharmaceuticals. Journal of Nuclear Medicine Technology. 41(1). 35–41. 62 indexed citations

14.

Callahan, Jason, Michael S. Hofman, Shankar Siva, et al.. (2013). High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 41(2). 343–349. 46 indexed citations

15.

Hofman, Michael S., et al.. (2012). High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. Journal of Medical Imaging and Radiation Oncology. 56(1). 40–47. 201 indexed citations

16.

Hofman, Michael S., Jean‐Mathieu Beauregard, Thomas W. Barber, et al.. (2011). ⁶⁸Ga PET/CT Ventilation–Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy. Journal of Nuclear Medicine. 52(10). 1513–1519. 80 indexed citations

17.

Eu, Peter, et al.. (2010). Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for Magnetic Resonance Imaging [MRI]. Figshare. 1 indexed citations

18.

Eu, Peter, et al.. (2010). Development and use of iron oxide nanoparticles (Part 1): Synthesis of iron oxide nanoparticles for MRI. Biomedical Imaging and Intervention Journal. 6(2). e12–e12. 160 indexed citations

19.

Ritchie, David, Linda Mileshkin, Dominic Wall, et al.. (2006). In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma. Cancer Immunology Immunotherapy. 56(2). 155–163. 65 indexed citations

20.

Kassiou, Michael, Karine Mardon, Andrew Katsifis, et al.. (1996). Radiosynthesis of [123I]N-methyl-4-iododexetimide and [123I]N-methyl-4-iodolevetimide: In vitro and in vivo characterisation of binding to muscarinic receptors in the rat heart. Nuclear Medicine and Biology. 23(2). 147–153. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact